@EricTopol: We're missing out on the value of genomics in medical practice. The cost (not charge) to do a polygenic risk score for …
Summary
A new review in the New England Journal of Medicine highlights that polygenic risk scores for various diseases cost only $20 and are informative for high-risk individuals across ancestries, underscoring the underutilized value of genomics in medical practice.
View Cached Full Text
Cached at: 09/24/26, 08:36 PM
We’re missing out on the value of genomics in medical practice. The cost (not charge) to do a polygenic risk score for all these diseases (Figure) and more is only $20 and they are informative for high-risk (top 5%) across ancestries A new review @NEJM https://nejm.org/doi/full/10.1056/NEJMra2413201?query=featured_secondary_home…
Similar Articles
China releases powerful DNA-screening AI tool for free to help fight rare diseases
Chinese researchers at BGI-Research released OneGenome, an open-source AI system that interprets gene mutations for clinical diagnosis, outperforming general LLMs like DeepSeek-v4, to help shorten the diagnostic odyssey for rare disease patients.
GENEB: Why Genomic Models Are Hard to Compare
GENEB is a large-scale diagnostic benchmark that evaluates 40 genomic foundation models across 100 tasks in 13 functional categories under a unified probing protocol, exposing that aggregate leaderboards are unstable and that architectural alignment often outweighs model scale. The work addresses the fragmented evaluation landscape in genomic machine learning, analogous to what MTEB did for NLP.
One Score, Two Decisions: Selective Prediction on the Rare-Disease Tail
This paper analyzes selective prediction systems for rare-disease diagnosis, demonstrating that small open-weight LLMs have low recall on ultra-rare diseases and exploring the use of score margins for decision-making with limitations.
Why Sample What You Can Enumerate? Exact Policy Optimization for Genomic Tool Selection
The paper introduces FGPO, a method for exact policy optimization in genomic tool selection that enumerates all possible tool subsets to outperform sampling-based approaches like GRPO.
@MSFTResearch: Talos was built to help resolve a major bottleneck in genomic medicine: human review time. The open-source system recov…
Talos is an open-source tool for automated, iterative genomic reanalysis that resolves the bottleneck of human review time, recovering 90% of diagnoses while surfacing only 1.3 candidate variants per patient.